COVID-19: Use of SGLT2s in Diabetes (Dapagliflozin/Canagliflozin/Empagliflozin/Ertugliflozin

The MHRA have advised that SGLT2 inhibitor treatment should be interrupted in patients who are hospitalised for major
surgical procedures or acute serious medical illnesses and ketone levels measured, preferably in blood rather than urine.
Treatment may be restarted when the ketone values are normal and the patient's condition has stabilised. Further information
can be found in the link in the resources section.